Preventive healthcare company Nightingale Health announced that it will open a laboratory in the U.S. In addition, the Englander Institute for Precision Medicine, a translational research hub at Weill Cornell Medicine in New York, has signed on as its first customer.
In a statement, the Helsinki-based company said that it signed a letter of intent with the Englander Institute in which the parties agree to collaborate on the adoption of Nightingale Health's proprietary technology in healthcare and medical research.
"Our precision metabolomics pilot project marks the beginning of a new era in healthcare. The vision is to use metabolic profiling to tailor treatments uniquely for each patient, advancing precision medicine to benefit patients globally," Olivier Elemento, director of the Englander Institute, said.
Nightingale will announce the location and opening schedule of the new laboratory at a later date.
The company said that the new laboratory will enable it to make its proprietary blood analysis technology locally available in the largest healthcare market in the world, along with expanding its partnerships within the medical research community.
"We are pleased to strengthen Nightingale Health's international presence by establishing a laboratory in the United States. This initiative complements our global network of laboratories located in Finland, Singapore, the United Kingdom and Japan, and allows us to serve the most ambitious precision medicine and healthcare projects in the world," Teemu Suna, Nightingale Health's CEO and founder, said in the firm's statement.
"The collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine will explore and implement ways for comprehensive risk assessment from our unique blood testing technology for patient treatment, health checks, and screening programs for multiple common chronic diseases."
